Galectin Therapeutics (GALT) Reports Q2 Loss of $0.14/Share

Galectin Therapeutics (NASDAQ: GALT) reported Q2 EPS of ($0.14), versus ($0.20) reported last year.

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

You May Also Be Interested In

• UBS says bull market has further to run
• Lowe's (LOW) PT Lowered to $275 at Guggenheim
• Walmart (WMT) PT Lowered to $130 at UBS as Investment Narrative's Competing Dynamics